LY2510924

LY2510924 · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LY2510924, covering 2019-07-23 to 2019-08-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2510924 and Durvalumab in Participants With Solid Tumors [Phase 1]